These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31985584)

  • 41. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. OSTEOPOROTIC FRACTURES DURING BISPHOSPHONATE DRUG HOLIDAY.
    Bindon B; Adams W; Balasubramanian N; Sandhu J; Camacho P
    Endocr Pract; 2018 Feb; 24(2):163-169. PubMed ID: 29144808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
    J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
    Lee DR; Lee J
    Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can long-term bisphosphonate use causes low-energy fractures? A case report.
    Dandinoğlu T; Akarsu S; Karadeniz M; Tekin L; Arıbal S; Kıralp MZ
    Osteoporos Int; 2014 Feb; 25(2):773-6. PubMed ID: 23824297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
    Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL
    Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Osteoporosis: how long should we treat?
    Sebba A
    Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):502-7. PubMed ID: 18971678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
    Netelenbos JC
    Ned Tijdschr Geneeskd; 2001 Jul; 145(28):1336-8. PubMed ID: 11484428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
    Anagnostis P; Paschou SA; Mintziori G; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Trémollieres FA; Goulis DG
    Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
    Hernandez I; Zhang Y
    J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates].
    Moro Álvarez MJ; Neyro JL; Castañeda S
    Med Clin (Barc); 2016 Jan; 146(1):24-9. PubMed ID: 26048545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.